Fostamatinib fails to improve outcomes in COVID-19 hypoxemia patients

December 6, 2024

Study design: This randomized, double-blind, placebo-controlled trial included 400 hospitalized adults with COVID-19 and hypoxemia who were randomly assigned to receive either fostamatinib or placebo, in addition to standard care. Primary endpoint was the number of days alive and free of supplemental oxygen by day 28.

Results: There was no significant difference between the fostamatinib and placebo groups in the primary endpoint. The adjusted odds ratio for oxygen-free days was 0.82 (95% CI, 0.58-1.17), indicating no benefit from fostamatinib. Secondary outcomes, including mortality and need for mechanical ventilation, also showed no significant differences.

Impact on clinical practice: The findings suggest that fostamatinib does not improve clinical outcomes for hospitalized COVID-19 patients with hypoxemia.

Source:

Collins SP, et al; ACTIV-4 Host Tissue Investigators. (2024, December 2). JAMA Netw Open. Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/39625722/